Molecular Imaging CRO
——
C-Ray with its molecular imaging technology is capable of conducting studies of radiopharmaceutical marking, in vivo imaging in small and large animals, preclinical efficacy in animals, pharmacokinetics, etc. to provide supportive data for registration of radiopharmaceutical INDs.
With its independent accelerator-based nuclide production technology, C-Ray produces the Cu-64 that meets the international IAEA quality standards, and processes it by marking to obtain highly emissive-pure radiodiagnostic drug molecules for preclinical animal imaging and biodistribution studies, as well as subsequent IIT imaging in the clinic.
Cu-64
With a full set of world-class pre-clinical research facilities and appropriate qualifications, as well as a sound IIT cooperation network, C-Ray can provide one-stop professional services from radiochemistry, pre-clinical research to IIT human research. Not only can we provide efficient solutions for the development of innovative radiopharmaceuticals, but we can also provide molecular imaging and companion diagnostic drug development services for XDC drugs.
Molecular imaging technology provides animals and human bodies with functional information of tissues and organs at the molecular level, shows microscopic activities such as cellular metabolism and signaling, and accurately locates the target tissues and organs, presenting fine anatomical structures, which are widely applied in the fields of oncology, cardiovascular, brain neurology research, and related drug development.
At present, C-Ray has the capability to independently produce diagnostic imaging nuclides such as Cu-64, Ga-68, Zr-89 and F-18. These nuclides can be used to mark small molecules, peptides, antibodies, and various engineered antibodies, such as nanoantibodies and antibody fragments. C-Ray is actively engaged in XDC marking process and quality control research, as well as in vitro cellular testing of marked drugs and in vivo, dynamic, continuous and different time-point imaging and biodistribution studies in small and large animals. These initiatives provide a solid foundation for validating the drug's durability, and significantly accelerate the development schedule while effectively reducing development costs.
It has been proved that Cu-64-marked nanoantibodies are well-targeting for tumors, with high local uptake and long retention
Through quality and process explorations with Zr-89-marked antibody conjugates, highly emissive-pure radiodiagnostic drug molecules are obtained and supplied for preclinical animal imaging and biodistribution studies, as well as subsequent IIT imaging in the clinic.
Zr-89
Rapid validation of Zr-89-marked antibodies
Fast lesion cumulation, most efficient distribution and high targeting ability for xenotransplanted tumor models.